Panel Discussion: Navigating Regulatory GMP Expectations to De-Risk Development & Enable Market Access

• Interpreting updated cell therapy GMP and advanced manufacturing technology expectations to leverage regulatory flexibility without compromising compliance
• Examining how evolving regulatory guidance influences clinical outcomes and commercialization pathways to align manufacturing quality with long-term market success

Speakers:

Seraphin Kuate

Director, Global CMC Regulatory, CAR T Cell Therapy

Bristol Myers Squibb

Sharon Anderson

Vice President, Scientific Affairs

Alliance for Regenerative Medicine